Results 31 to 40 of about 57 (45)

Safety of Drugs Used in Difficult-to-Treat Epileptic Syndromes: A Disproportionality Analysis Using the Eudravigilance Database. [PDF]

Pharmaceuticals (Basel)
Scala A, Trunfio TA, Pennisi C, Lombardo GE, Micale V, Martino SD, Fiorenza G, Graziano ACE, Briglia M, Allia F, Giurdanella G, Malaguarnera R, Battaglia R, Gozzo C, Palumbo FE, Vetro C, Improta G, Toro MD, Drago F, Romano GL, Gozzo L.   +20 more
europepmc   +1 more source

PAtient-Centric epilepsy clinical trIal model For Improved health outcomes using Cannabidiol (PACIFIC study)-a methodology for developing patient-centred clinical trials in rare epilepsy syndromes. [PDF]

BMC Med Res Methodol
Truong L, Stettaford T, Watt K, Ghafournia N, Anetko P, Shin J, Pierce K, Lawson JA, Martin JH.   +8 more
europepmc   +1 more source

Fenfluramine for seizures associated with Dravet syndrome and Lennox-Gastaut syndrome. [PDF]

Aust Prescr
europepmc   +1 more source

ASENT 2022 Annual Meeting. [PDF]

Neurotherapeutics, 2022
europepmc   +1 more source

Innovative drug discovery strategies in epilepsy: integrating next-generation syndrome-specific mouse models to address pharmacoresistance and epileptogenesis. [PDF]

Expert Opin Drug Discov
Barker-Haliski M, Hawkins NA.
europepmc   +1 more source

Fenfluramine for the treatment of status epilepticus: use in an adult with Lennox-Gastaut syndrome and literature review. [PDF]

Neurol Res Pract
Strzelczyk A, Becker H, Tako L, Hock S, Hattingen E, Rosenow F, Mann C.   +6 more
europepmc   +1 more source

Poster Abstracts - Academy of Managed Care Pharmacy Virtual 2021. [PDF]

J Manag Care Spec Pharm, 2021
europepmc   +1 more source

Optimal dose of fenfluramine in adjuvant treatment of drug-resistant epilepsy: evidence from randomized controlled trials. [PDF]

Front Neurol
Xu Y, Chen D, Liu L.
europepmc   +1 more source

Poster Abstracts - Academy of Managed Care Pharmacy NEXUS 2021. [PDF]

J Manag Care Spec Pharm, 2021
europepmc   +1 more source

Drug repurposing for rare: progress and opportunities for the rare disease community. [PDF]

Front Med (Lausanne)
Jonker AH, O'Connor D, Cavaller-Bellaubi M, Fetro C, Gogou M, 't Hoen PAC, de Kort M, Stone H, Valentine N, Pasmooij AMG.   +9 more
europepmc   +1 more source